Depression Clinical Trial
Official title:
Serotonin1A Receptor and Serotonin Transporter Imaging In Mood Disorders
The purpose of this study is to evaluate the function of certain brain chemicals and
receptors in patients with mood disorders. This study will also examine how the stress
hormone cortisol affects brain function.
Data suggest that serotonin 1A (5-HT1A) receptor function is abnormal in patients with mood
disorders, such as major depressive disorder (MDD) and bipolar disorder (BP). However, these
data are limited because they are based on small sample sizes. In this study, PET scans will
be used to compare 5-HT1A receptor binding potential between mood disorder patients and
healthy volunteers.
All participants will have an initial medical and psychiatric evaluation. Depression
severity, anxiety, negative thinking, level of functioning, intelligence, and cognitive
functions will be measured. Urine, saliva, and blood will be collected. Women will have a
pregnancy test and tests to determine menstrual phase and time of ovulation. Participants
will undergo magnetic resonance imaging (MRI) and PET scans of the brain. Some participants
will have other procedures such as a lumbar puncture. Participants with Cushing's disease
will undergo imaging as a comparison group.
Multiple lines of evidence suggest that serotonin1A (5-HT1A) receptor and serotonin
transporter (5-HTT) function is abnormal in major depressive disorder (MDD) and that somatic
antidepressant treatments effect changes in the function of these systems that are relevant
to their therapeutic mechanisms. The data supporting these hypotheses have been obtained by
assessing neuroendocrine and temperature responses to 5-HT1A agonists in MDD subjects,
measuring 5-HT1A receptor and 5-HTT binding in brain tissue acquired post mortem from small
samples of MDD subjects, and examining effects on 5-HT1A receptor function in rats following
antidepressant drug (AD) administration. The recent development of highly selective 5-HT1A
receptor and 5-HTT radioligands for positron emission tomography (PET) imaging made direct,
noninvasive exploration of the central serotonin sites binding possible. Two studies
conducted using one of these, [carbonyl-11C]-WAY-100635, found reduced 5-HT1A receptor
binding potential (BP) in the mesiotemporal cortex, the raphe, and the prefrontal cortex
(PFC). Pilot data from these studies suggested that the abnormal reduction in 5-HT1A receptor
BP is more prominent in bipolar disorder (BD) than MDD subjects (i.e., unipolar depressives)
who did not have bipolar relatives, and that it exists independently of mood state.
However, these data have the limitations that the subject samples studied in these
preliminary post mortem and PET series have been small, and that [carbonyl-11C]WAY-100635
uptake is difficult to quantitate in PET images. Therefore, these observations require
replication in subject samples large enough to establish main effects of diagnostic subtype
using a 5-HT1A receptor radioligand that can be validly quantitated. A selective 5-HT1A
receptor radioligand suitable for this purpose, [18F]FC-WAY100635 ([18F]FCWAY), has recently
been developed at the NIH. In addition, a recently developed selective 5-HTT ligand, [11C]
DASB provides a unique opportunity to image the 5-HTT in the same depressed sample.
The proposed study will advance knowledge regarding the neurobiology of mood disorders by
employing PET and [18F]FCWAY and [11C] DASB to compare 5-HT1A receptor BP between mood
disordered and healthy control subjects in the mesiotemporal cortex, raphe, anterior
cingulate gyrus, and left orbital cortex. The following hypotheses, based upon pilot data
acquired using [carbonyl-11C]-WAY-100636, will be tested: 1) Depressives have reduced 5-HT1A
receptor binding relative to healthy controls. 2) Bipolar depressives will have significantly
greater reductions in 5-HT1A receptor binding than unipolar depressives with only unipolar
relatives. A pilot study in which bipolar depressives are treated with lithium or divalproex
and then re-imaged will test the third hypothesis, that 5-HT1A receptor binding will increase
in bipolar subjects during mood stabilizer therapy.
Finally, because central 5-HT1A receptor density is down-regulated in rodents by
corticosterone administration and by stress-mediated corticosterone secretion, assessments of
hypothalamic-pituitary-adrenal (HPA) axis activity (which is commonly elevated in MDD and
BD), will be assessed to determine whether down-regulation of 5-HT1A receptors correlates
with cortisol hypersecretion in mood disorders. Because this down-regulation may play a
compensatory role to reduce cortisol secretion, neuroendocrine assessments of long-standing
rather than acute hypercortisolism and of the pathophysiological diathesis to hypersecrete
cortisol will be emphasized as providing the most sensitive correlates of reduced 5-HT1A
receptor binding. A medical control group with Cushing's Disease will also be imaged to
determine whether pathological elevation of glucocorticoid levels down-regulates 5-HT1A
receptor expression in humans, as it does in rats.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05777044 -
The Effect of Hatha Yoga on Mental Health
|
N/A | |
Recruiting |
NCT04977232 -
Adjunctive Game Intervention for Anhedonia in MDD Patients
|
N/A | |
Recruiting |
NCT04680611 -
Severe Asthma, MepolizumaB and Affect: SAMBA Study
|
||
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Completed |
NCT04512768 -
Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Completed |
NCT04476446 -
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
|
Phase 3 | |
Recruiting |
NCT02783430 -
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
|
Phase 2/Phase 3 | |
Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
Completed |
NCT04598165 -
Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support
|
N/A | |
Completed |
NCT03457714 -
Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
|
||
Recruiting |
NCT05956912 -
Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
|
||
Completed |
NCT05588622 -
Meru Health Program for Cancer Patients With Depression and Anxiety
|
N/A | |
Recruiting |
NCT05234476 -
Behavioral Activation Plus Savoring for University Students
|
N/A | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Enrolling by invitation |
NCT03276585 -
Night in Japan Home Sleep Monitoring Study
|
||
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A |